Dr. Aude Segaliny, PhDVP of Research & Development at Amberstone BiosciencesSpeaker
Agenda Sessions
Rewriting the Safety–Efficacy Balance: Engineering Conditionally Activated TCEs for Solid Tumors.
, 5:45pmView Session
